Emergence of resistance to ciprofloxacin in Neisseria meningitidis in Brazil

• Autores: Gorla, María Cecilia; Cassiolato, Ana Paula; Pinhata, Juliana Maira Watanabe; de Moraes, Camile; Corso, Alejandra; Gagetti, Paula; Lemos, Ana Paula
• Año de publicación: 2018
• Idioma: inglés
• Tipo de recurso: artículo
• Fuente: Journal of Medical Microbiology 2018; 67:286-288
• Materia: Ciprofloxacino; Antibacterianos; Brasil; Girasa de ADN; Topoisomerasa de ADN IV; Farmacorresistencia Bacteriana; Fluoroquinolonas; Humanos; Infecciones Meningocócicas; Pruebas de Sensibilidad Microbiana; Tipificación de Secuencias Multilocus; Mutación; Neisseria gonorrhoeae; Neisseria meningitidis; Quinolonas
• Institución: Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"

Fil: Gorla, Maria Cecília. Adolfo Lutz Institute. Bacteriology Department; Brasil.
Fil: Cassiolato, Ana Paula. Adolfo Lutz Institute. Bacteriology Department; Brasil.
Fil: Pinhata, Juliana Maira Watanabe. Adolfo Lutz Institute. Bacteriology Department; Brasil.
Fil: de Moraes, Camile. Ministry of Health. Secretariat of Health Surveillance; Brasil.
Fil: Corso, Alejandra. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Gagetti, Paula. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Lemos, Ana Paula. Adolfo Lutz Institute. Bacteriology Department; Brasil.
To prevent secondary invasive meningococcal disease (IMD) cases and outbreaks, antimicrobial prophylaxis of high-risk contacts is indicated. This study reports two ciprofloxacin-resistant Neisseria meningitidis strains in Brazil. The 3523 N. meningitidis isolates collected throughout Brazil from 2009 to 2016 were evaluated for antimicrobial resistance. Meningococcal isolates showing minimal inhibitory concentrations, MICs≥0.125µg ml-1 to ciprofloxacin, were analysed to determine the presence of mutations in the quinolone resistance-determining regions (QRDRs) of gyrA and parC genes. Two ciprofloxacin-resistant N. meningitidis isolates were found, both presenting a single mutation in the quinolone resistance-determining region of the gyrA gene. These results confirmed that ciprofloxacin is still a first-line drug for chemoprophylaxis. However, we highlight the importance of continued surveillance to monitor the trends of N. meningitidis susceptibility profiles to the antimicrobials recommended for chemoprophylaxis and IMD treatment.